We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

An Open Label and Safety Study of the Safety Of SPARC1104

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01797185
Recruitment Status : Active, not recruiting
First Posted : February 22, 2013
Last Update Posted : May 25, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis

Condition or disease Intervention/treatment Phase
Spasticity Drug: SPARC1104 Phase 3

Detailed Description:
Safety study of SPARC1104

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Actual Study Start Date : April 4, 2013
Estimated Primary Completion Date : July 2017
Estimated Study Completion Date : July 2017
Arms and Interventions

Arm Intervention/treatment
Experimental: SPARC1104 Drug: SPARC1104
Subjects will receive SPARC1104


Outcome Measures

Primary Outcome Measures :
  1. No. of participants with adverse events [ Time Frame: 26 weeks ]
  2. No. of participants with adverse vital signs [ Time Frame: 26 weeks ]
  3. Number of participants with adverse laboratory parameters [ Time Frame: 26 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Willingness to participate and give written informed consent
  • Men and women ≥ 18 years of age
  • Sexually active women who are of child bearing potential will practice an acceptable method of birth control for the duration of the trial as judged by the investigator. Examples of acceptable contraception are: condoms, foams, jellies, diaphragm, intrauterine device, oral or long-acting injected contraceptives, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or having a partner who is incapable of initiating conception. The practice of contraception must have started at least 3 months prior to trial entry.
  • If female, negative pregnancy test result at Screening
  • Diagnosed with MS and a known history of spasticity
  • Meet one of the following criteria

    • Subjects who completed the double-blind randomized withdrawal phase (Part 3) of trial CLR_09_21 with no major protocol violation
    • Subjects who are newly diagnosed with spasticity due to MS with no history of treatment using any anti-spasticity medications, or, with a history of spasticity due to MS but with no previous exposure to baclofen treatment
    • Subjects who are receiving a stable baclofen IR dose (ie, a dose of 10 mg to 80 mg daily, having started at least 30 days prior to enrollment)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01797185


  Show 51 Study Locations
Sponsors and Collaborators
Sun Pharma Advanced Research Company Limited
More Information

Responsible Party: Sun Pharma Advanced Research Company Limited
ClinicalTrials.gov Identifier: NCT01797185     History of Changes
Other Study ID Numbers: CLR_11_04
First Posted: February 22, 2013    Key Record Dates
Last Update Posted: May 25, 2017
Last Verified: December 2016

Keywords provided by Sun Pharma Advanced Research Company Limited:
baclofen, spasticity

Additional relevant MeSH terms:
Muscle Spasticity
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms